Professor of Cardiology, MD, FESC, FACC, FAHA
Oslo University Hospital, Ulleval
University of Oslo, Norway
Short synopsis of CV
Dan Atar is Head of Research at Oslo University Hospital Ulleval, Dept. of Mecidine, Oslo, Norway, and holds a full Professorship in Cardiology at the University of Oslo, Norway, along with a Visiting Associate Professorship at the Johns Hopkins University, Baltimore, Maryland, USA.
Dan Atar trained in Denmark, Switzerland, and the United States before receiving his board certification in Internal Medicine and Cardiology in 1995. His research focuses on myocardial biomarkers, myocardial function, heart failure and cardiovascular pharmacology. He has written over 400 articles and book chapters (H-index 64) and holds the fellowship-titles FESC, FACC, and inaugural FAHA. Dan Atar is the Past-Chairman of the ESC Working Group on Cardiovascular Pharmacotherapy. He was chairing an EU-FP7 research consortium (“Mitocare”) to study reperfusion injury in STEMI and chairs currently the national BETAMI-trial. He also acts as partner in the EU-Horizon2020 “Climate-and-health” project. Dan Atar was on a number of ESC guideline writing committees, amongst others the “2010, 2012 and 2016 ESC Guideline on Atrial Fibrillation” as well as the 2012 STEMI-guideline and the 2018 “Universal Definition of AMI”. In 2012 Dan Atar was elected as Councillor and Board member of the ESC. Further, in 2014, he was elected as Vice-President of the ESC for the 2014-2016 Board. For his scientific achievements, he earned a doctor honoris causa in 2015 and appears on the 2016 and 2017 Thomson-Reuters list of “the most cited scientists of the world”. In 2018, Dan Atar was elected Treasurer/Secretary of the ESC Board.
SESSION 15 -THROMBOSIS
Tuesday, June 11, 2019